To include your compound in the COVID-19 Resource Center, submit it here.

FFP proves hard to avoid

Many a biotech company has seen a compound make it all the way to Phase III only to fail to meet the primary end point. But to the dismay of ATIII LLC, a joint venture between Genzyme Transgenics Corp. and Genzyme General, positive Phase III data were not enough to

Read the full 502 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers